Leczna

• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A multicentre, intra-patient randomised controlled Phase III study to confirm the efficacy and safety of denovoSkin™, a bilayer engineered c … Recruiting
  2023-507717-94-00 5 2024-12-06 Deep partial and full-thickness burns
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 6 2024-07-31 Moderately to Severely Active Crohn’s Disease
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• A Study of Susceptibility to Baloxavir Marboxil in Patients with Influenza and its transmission to their household contacts Ended recruitment
  2023-504672-22-00 5 2023-11-24 Influenza
• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended recruitment
  2024-515027-11-00 4 2023-06-29 Crohn’s disease
• Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended recruitment
  2022-500290-14-01 4 2023-05-11 Colitis ulcerative
• Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended recruitment
  2023-507974-42-00 4 2021-12-01 Moderate to Severe Ulcerative Colitis
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• Effects of single-pill combination of telmisartan/amlodipine and telmisartan/amlodipine/hydrochlorothiazide on 24-hour blood pressure (BP) r … Ended
  2023-504812-13-00 11 2024-05-06 Arterial hypertension
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
• Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended
  2023-508177-85-00 5 2024-03-12 Healthy volunteers (Meningococcal infection)
• A Phase 2 Safety and Immunogenicity Study of a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers Ended
  2023-505154-18-00 4 2023-11-02 Pneumococcal Infections
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended
  2024-511089-36-00 4 2023-03-17 Crohn’s disease
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok

Showing 1–23 of 23 trials